NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc., (OTCBB: GTHP) (OTCQB: GTHP), today announced that it has successfully completed electromagnetic compatibility testing, one of two major categories of third-party testing required to label the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, with the ISO 60601 Edition 3 CE Mark and Canadian Standards Association (CSA) Mark. “Electromagnetic compatibility testing can be the most challenging of the major certification components, and we are pleased to report our successful outcome,” said Richard Fowler, Senior Vice President of Engineering at Guided Therapeutics. “Basic safety testing, the next phase of work to be done at the third-party testing facility, is expected to be completed in the next two to three weeks.”
